Astrazeneca has announced
the purchase of oncology
researcher Amplimmune, boosting
its pipeline with “multiple earlystage
assets” for its immunemediated
cancer therapy portfolio.
The deal is worth up to US$500m,
with an initial $225m payment and
further milestone-based funding.The above article was sent to subscribers in Pharmacy Daily's issue from 28 Aug 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Aug 13
THOUGH women make up 60% of pharmacy graduates and pharmacists, they hold only 34% of leadership and ownership roles, according to Andria Aird, a community pharmacist, pharmacy owner, and Board Director of Blooms The Chemist.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.